KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Invested Capital (2016 - 2026)

Neogenomics filings provide 17 years of Invested Capital readings, the most recent being $828.8 million for Q1 2026.

  • On a quarterly basis, Invested Capital fell 6.7% to $828.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $828.8 million, a 6.7% decrease, with the full-year FY2025 number at $836.6 million, down 7.29% from a year prior.
  • Invested Capital hit $828.8 million in Q1 2026 for Neogenomics, down from $836.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $1.1 billion in Q1 2022 to a low of $828.8 million in Q1 2026.
  • Median Invested Capital over the past 5 years was $923.4 million (2024), compared with a mean of $932.1 million.
  • The widest YoY moves for Invested Capital: up 27.41% in 2022, down 10.93% in 2022.
  • Neogenomics' Invested Capital stood at $998.0 million in 2022, then dropped by 5.66% to $941.5 million in 2023, then dropped by 4.16% to $902.3 million in 2024, then fell by 7.29% to $836.6 million in 2025, then dropped by 0.93% to $828.8 million in 2026.
  • The last three reported values for Invested Capital were $828.8 million (Q1 2026), $836.6 million (Q4 2025), and $838.3 million (Q3 2025) per Business Quant data.